ATRACURIUM BESYLATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Atracurium Besylate, and when can generic versions of Atracurium Besylate launch?
Atracurium Besylate is a drug marketed by Baxter Hlthcare, Baxter Hlthcare Corp, Eugia Pharma, Hikma, Hospira, Hospira Inc, Meitheal, Mylan Labs Ltd, Teva Parenteral, Watson Pharms Teva, and Watson Labs Inc. and is included in twenty-two NDAs.
The generic ingredient in ATRACURIUM BESYLATE is atracurium besylate. There are sixteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the atracurium besylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Atracurium Besylate
A generic version of ATRACURIUM BESYLATE was approved as atracurium besylate by HIKMA on July 18th, 1997.
Summary for ATRACURIUM BESYLATE
US Patents: | 0 |
Applicants: | 11 |
NDAs: | 22 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 101 |
Clinical Trials: | 14 |
Patent Applications: | 771 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ATRACURIUM BESYLATE at DailyMed |
Recent Clinical Trials for ATRACURIUM BESYLATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Tanta University | N/A |
Cairo University | Phase 4 |
Theodor Bilharz Research Institute | Phase 4 |
Pharmacology for ATRACURIUM BESYLATE
Drug Class | Nondepolarizing Neuromuscular Blocker |
Physiological Effect | Neuromuscular Nondepolarizing Blockade |